Longevity In A Capsule: Jupiter Neurosciences Launches First Three Supplements Under Nugevia(TM) Brand

About this update from Jupiter Neurosciences, Inc.

[{"type":"text","content":"By Meg Flippin Benzinga\nDETROIT, MICHIGAN - August 19, 2025 (NEWMEDIAWIRE) - Jupiter Neurosciences Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company developing JOTROL(TM) - an enhanced orally administered resveratrol formulation known for its antioxidant and anti-inflammatory effects - is solidifying its two-pronged business approach with the launch of Nugevia(TM), its direct-to-consumer longevity product line.\n Nugevia leverages JOTROL to improve mitochondrial support, mental clarity and \"beauty from within.\" It's a big milestone for Jupiter Neurosciences as it harmonizes its strategy to developing drugs to treat central nervous system (CNS) disorders and rare diseases, while developing a direct-to-consumer (DTC) arm to drive revenue and cashflow, reducing its dependency on the slower clinical process in which it can take years for a drug to go from the developmental stage to the market.\nNugevia is that direct-to-consumer play, and addresses a big market, as people around the world seek to not only live longer but improve their quality of life as they do it. \nThe scientifically backed longevity market is booming and is expected to experience significant growth in the years to come. Back in 2023, it was worth $65 billion, and it's projected to hit $314 billion by 2030. When you combine mind, beauty and energy, Jupiter Neurosciences pegs the addressable market at $8 trillion.\nLongevity In A Bottle \nNugevia's products, which are powered by the underlying patent-protected resveratrol formulation, JOTROL, are backed by more than eight years of pharmaceutical development. JOTROL is designed and intended to deliver therapeutically relevant, safe levels of resveratrol. In addition to its antioxidant and anti-inflammatory effects, resveratrol activates PARP-1 - an important protein in DNA repair and stress response - improves cardiovascular health, enhances cognitive function and is antibacterial and antiviral against food-borne pathogens.\n\"The launch of Nugevia is the natural next step in translating our science into broad, real-world impact,\" said Christer Rosen, Chairman and CEO of Jupiter Neurosciences. \"By building on the same proprietary technology platform that underpins our prescription drug development, we're delivering a differentiated consumer offering with unmatched bioavailability and scientific credi...

More updates from Jupiter Neurosciences, Inc.